Abstract Number: 105 • 2020 Pediatric Rheumatology Symposium
Discovering the Implications of Adiposity in Juvenile Dermatomyositis
Background/Purpose: Obesity and pro-inflammatory cytokines produced by adipocytes have been linked to many outcomes including disease severity, treatment response, and disease progression in several autoimmune…Abstract Number: 106 • 2020 Pediatric Rheumatology Symposium
Childhood-onset Takayasu Arteritis: A Single Center Case Series of Atypical and Varied Presentations
Background/Purpose: Childhood-onset Takayasu arteritis is a rare inflammatory vessel disease that predominantly affects the aorta and its major branches. Clinical presentation at disease onset can…Abstract Number: 107 • 2020 Pediatric Rheumatology Symposium
Defining the Prevalence of Depression and Anxiety Symptoms in Adolescents with Juvenile Idiopathic Arthritis
Background/Purpose: We aimed to evaluate the prevalence of depressive and/or anxiety symptoms in adolescents with juvenile idiopathic arthritis (JIA) and explore the association with demographic…Abstract Number: 108 • 2020 Pediatric Rheumatology Symposium
A Multinational Study of Thrombotic Microangiopathy in Macrophage Activation Syndrome: A Dreadful Condition Which Is Likely Underrecognized
Background/Purpose: Macrophage activation syndrome (MAS) is a severe complication of rheumatologic conditions, mainly systemic juvenile idiopathic arthritis (sJIA), and is classified among the secondary forms…Abstract Number: 109 • 2020 Pediatric Rheumatology Symposium
Incidence, Contributing Factors, and Impact of Diagnostic Delay in Juvenile Idiopathic Arthritis: Analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Background/Purpose: While early treatment of patients with newly diagnosed juvenile idiopathic arthritis (JIA) is an area of active study, delayed diagnosis of JIA is poorly…Abstract Number: 110 • 2020 Pediatric Rheumatology Symposium
Consequences and Predictors of Persisting Pain in Children with Juvenile Idiopathic Arthritis: A Case Control Study Nested in the ReACCh-Out Cohort
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common rheumatic disease of childhood. Pain is a distressing and prevalent feature of JIA and can decrease…Abstract Number: 111 • 2020 Pediatric Rheumatology Symposium
WITHDRAWN
Abstract Number: 112 • 2020 Pediatric Rheumatology Symposium
WITHDRAWN
Abstract Number: 113 • 2020 Pediatric Rheumatology Symposium
Evaluation of B-cell Depletion with Rituximab and IVIG Concurrent Treatment in Pediatric Autoimmune Brain Disease
Background/Purpose: Rituximab is standard therapy in treating autoimmune brain disease (ABD) including refractory autoimmune encephalitis (AE) and Neuromyelitis Optica Spectrum Disease (NMOSD). Recommendations for continuing…Abstract Number: 114 • 2020 Pediatric Rheumatology Symposium
Musculoskeletal Ultrasound Study in Childhood Arthritis: A Limited Examination
Background/Purpose: A challenge in the management of Juvenile Idiopathic Arthritis (JIA) is most of the core set of assessment measurements are subjective by nature. A…Abstract Number: 115 • 2020 Pediatric Rheumatology Symposium
Carbohydrate and Sugar Intake Predict Pain in Teens with Active JIA Disease but Not in Teens in Remission or Controls: A Cross-Sectional, Case-Control Metabolomics Pilot Study
Background/Purpose: The purpose of this study is to define the relationships between pain and carbohydrate metabolism in teens with active juvenile idiopathic arthritis (JIA), teens…Abstract Number: 116 • 2020 Pediatric Rheumatology Symposium
Patterns of Etanercept Use in the Childhood Arthritis and Rheumatology Research Alliance Juvenile Idiopathic Arthritis Registry
Background/Purpose: Etanercept (ETN) is an anti-tumor necrosis factor (anti-TNF) therapy that is FDA approved for the treatment of polyarticular juvenile idiopathic arthritis (JIA). This study…Abstract Number: 117 • 2020 Pediatric Rheumatology Symposium
Family Impact of Juvenile Localized Scleroderma
Background/Purpose: Juvenile localized scleroderma (jLS) is a rare autoimmune disease that can lead to significant morbidity. Previous studies have focused on predictors of patient health-related…Abstract Number: 118 • 2020 Pediatric Rheumatology Symposium
Long-Term Outcomes in Children Born to Anti-Ro and/or anti-La Positive Mothers
Background/Purpose: Neonatal Lupus Erythematosus (NLE) is an acquired autoimmune disorder associated with the transplacental passage of maternal anti-Ro and/or anti-La antibodies. NLE manifestations include cardiac,…Abstract Number: 119 • 2020 Pediatric Rheumatology Symposium
Actual Medication Usage of Patients with Juvenile Onset Systemic Lupus Erythematosus Using Japanese Health Insurance Database
Background/Purpose: Background: Immunosuppressive therapy is the mainstay of treatment of child systemic lupus erythematosus (cSLE). However until very recently, the treatment of cSLE lacked uniformity.…
- « Previous Page
- 1
- …
- 979
- 980
- 981
- 982
- 983
- …
- 2607
- Next Page »
